Medical researchers at the University of Nottingham and NIHR Nottingham Biomedical Research Centre are part of a major new international research project to improve the safety and regulation in the development of drugs.
The team of experts in drug-induced liver injury will be members of the Translational Safety Biomarker Pipeline (TransBioLine) – a pioneering project which will generate data to support the development of novel safety biomarkers for five target organ systems (kidney, liver, pancreas, vascular and central nervous system) for use in drug development. The project is part of the EU’s Innovative Medicines Initiative (IMI)1.
Robust biomarkers are vital in the creation of new drugs to improve diagnosis, monitor drug activity and therapeutic effect. They help guide the development of safer, more targeted treatments for chronic diseases but up to now the process of identifying new and reliable biomarkers has been difficult. The new ‘pipeline’ has been set up to address this and speed up the discovery and development of specific biomarkers for complex chronic diseases.
The TransBioLine Project is a consortium of 27 partners across pharmaceutical companies, small and medium-sized enterprises, and academic institutions from 10 European countries, and is coordinated by the University of Zurich with Pfizer Inc. as the industry lead. It is funded by the IMI Joint Undertaking as a public-private partnership, with a budget of 28M€ and will be active through 2024.
Professor Guruprasad Aithal, the Deputy Academic Co-ordinator for TransBioLine and the 'Drug-induced liver injury (DILI)' work package lead, said: “TransBioLine is an enormous opportunity to turn science into clinical practice to improve safe use of medication. It will boost NIHR Nottingham BRC researchers who have led discoveries in DILI field over the past two decades. Drs Jane Grove and Stuart Astbury are contributing to the discovery and evaluation of new tests to identify liver injury early and reduce patient harm and Beth Robinson will be the project coordinator for the DILI work package.”
Shashi Ramaiah, Executive Director, Pfizer Drug Safety Research & Development and TransBioLine Lead Scientist said: “One of the major gaps in drug development is the lack of qualified safety biomarkers with acceptable precision and accuracy for safety monitoring during clinical development. The TransBioLine Project provides a unique opportunity to access a large expert and knowledge network, including data and samples from clinical trials, to enable the global safety qualification of identified novel biomarkers. Implementing qualified safety biomarkers in early clinical trials will mitigate safety attrition of promising drug candidates and advance projects to clinics through higher-quality and better-informed decision making.”
Michael Merz, Consortium Coordinator, University of Zurich, said, “This is one of the largest public-private partnerships of European and American scientists that focuses on the development and regulatory qualification of new safety biomarkers. These include indicators of tissue damage like liquid biopsy, biomarkers that could facilitate patient stratification, and standardized tests for detection of these biomarkers. These new markers are ultimately expected to not only improve safety of new and approved drugs, but also to contribute to better diagnosis and management of acute and chronic diseases. It is really exciting to see years of enthusiastic preparation translating into this project going forward now.”
When the project ends in 2024, the consortium will have established an infrastructure and processes to continue biomarker research across a comprehensive network of industry, academic institutions, and small and medium-sized enterprises, and it will be able to provide the scientific community, industry and patients with detailed data and information across a large spectrum of advanced safety biomarkers.
1About the Innovative Medicines Initiative
The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is working to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need.
— Ends —
Our academics can now be interviewed for broadcast via our Media Hub, which offers a Globelynx fixed camera and ISDN line facilities at University Park campus. For further information please contact a member of the Communications team on +44 (0)115 951 5798, email firstname.lastname@example.org or see the Globelynx website for how to register for this service.
For up to the minute media alerts, follow us on Twitter
Notes to editors:
The University of Nottingham is a research-intensive university with a proud heritage, consistently ranked among the world's top 100. Studying at the University of Nottingham is a life-changing experience and we pride ourselves on unlocking the potential of our 44,000 students - Nottingham was named both Sports and International University of the Year in the 2019 Times and Sunday Times Good University Guide, was awarded gold in the TEF 2017 and features in the top 20 of all three major UK rankings. We have a pioneering spirit, expressed in the vision of our founder Sir Jesse Boot, which has seen us lead the way in establishing campuses in China and Malaysia - part of a globally connected network of education, research and industrial engagement. We are ranked eighth for research power in the UK according to REF 2014. We have six beacons of research excellence helping to transform lives and change the world; we are also a major employer, proud of our Athena SWAN silver award, and a key industry partner- locally and globally.